Upper Respiratory Tract Infections (URTI): e.g. otitis media, resistant URTI where treatment failure may carry significant risk.
Lower Respiratory Tract Infections: e.g. bronchitis.
Urinary Tract Infections (UTI): e.g. cystitis, cystourethritis, pyelonephritis.
Effective against Streptococcus pneumoniae, Streptococcus pyogenes, Escherichia coli, Proteus mirabilis, Klebsiella spp., Haemophilus influenzae (β‑lactamase positive and negative), Moraxella catarrhalis (β‑lactamase positive and negative), Enterobacter spp.
Highly stable in presence of β‑lactamase enzymes.

Adults & children >10 years: 200–400 mg daily (single or divided dose).
Children: 8 mg/kg/day (single or divided).
- 6 months–1 year: 3.75 ml daily
- 1–4 years: 5 ml daily
- 5–10 years: 10 ml daily
- Typhoid: 5 mg/kg twice daily for 10–14 days
Elderly: same as adults; adjust if severe renal impairment.
Renal impairment:
- CrCl ≥20 ml/min: normal dose.
- CrCl <20 ml/min: max 200 mg once daily.
- Dialysis: same as CrCl <20 ml/min.
Usual course: 7 days (extend up to 14 days if required).

Generally well tolerated.
GI: diarrhea, stool changes, nausea, abdominal pain, dyspepsia, vomiting, flatulence, pseudomembranous colitis.
CNS: headache, dizziness.
Hypersensitivity: rash, pruritus, urticaria, drug fever, arthralgia.
Hematology: thrombocytopenia, leukopenia, eosinophilia.
Mild transient liver/renal test changes.
Others: genital pruritus, vaginitis.

Caution in patients hypersensitive to penicillins (cross‑allergenicity possible).
Severe allergic reactions (including anaphylaxis) reported.
Caution in renal impairment.
Broad‑spectrum antibiotics may cause Clostridium difficile–associated diarrhea.

No specific antidote. Gastric lavage may be indicated.
Not significantly removed by dialysis.
Single doses up to 2 g in healthy adults showed similar adverse profile to recommended doses.